India Generic Drugs Market

India Generic Drugs Market Analysis

The India Generic Drugs Market size is estimated at USD 26.31 billion in 2025, and is expected to reach USD 35.40 billion by 2030, at a CAGR of 6.10% during the forecast period (2025-2030).

India's generic drug market, driven by its advanced pharmaceutical manufacturing capabilities, cost-effective production processes, and skilled workforce, has positioned itself as a key player in the global pharmaceutical industry. As the largest supplier of generic medicines globally, the market is further supported by government initiatives such as the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to deliver high-quality generics at affordable prices.

The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, coupled with a sedentary lifestyle and a growing geriatric population, is driving market expansion. Older populations are more prone to comorbidities, necessitating effective medications with convenient drug administration methods. This trend underscores the critical role of innovative drug delivery systems in addressing the healthcare needs of aging populations, thereby fostering market growth.

India's escalating chronic disease burden is significantly boosting the demand for generic medications, presenting a substantial growth opportunity for the market. For example, as of May 2024, approximately 6,351 cases of Seasonal Influenza A (H1N1) were recorded in India, as reported by the Integrated Disease Surveillance Programme (IDSP), National Centre for Disease Control (NCDC), Delhi, in its November 2024 publication. Additionally, the Indian Council of Medical Research (ICMR) 2023 report projected that lung cancer cases, currently at 70,275, will double by 2025. This anticipated surge in cancer cases is expected to drive market growth, as it highlights the urgent need for affordable and accessible treatment options. The rising prevalence of chronic diseases and cancer underscores the importance of expanding the availability of generic medications to meet the growing healthcare demands.

Government initiatives, such as the Pradhan Mantri Bhartiya Jan Aushadi Yojana, are significantly driving the awareness and accessibility of generic medications in India. This program, which ensures the availability of quality medicines at affordable prices, has witnessed substantial adoption among average to low-income groups across all Indian states. These initiatives play a critical role in addressing the gap between healthcare demand and affordability, thereby fostering market expansion. Furthermore, in November 2023, the Union Health Ministry introduced generic drugs aimed at facilitating the treatment and management of four medical conditions: Tyrosinemia-Type 1, Gaucher's Disease, Wilson's Disease, and Dravet-Lennox Gastaut Syndrome (a severe form of epilepsy). Consequently, such government-led measures supporting the adoption of generic drugs are expected to drive market growth during the forecast period.

In conclusion, the market is poised for significant growth, driven by the increasing burden of chronic diseases, an aging population, heightened awareness initiatives, and innovative product launches. However, stringent government regulations may act as a potential barrier to growth. Addressing these regulatory challenges while leveraging the growing demand for affordable healthcare solutions will be critical for sustained market development over the forecast period.

India Generic Drugs Market Trends

Oral Segment is Expected to Witness a Significant Growth Over the Forecast Period

Oral generics are the simplest, most convenient, and safest means of drug administration, convenient for repeated and prolonged use, and can be self-administered and pain-free hence they are the most used and most manufactured for of drugs even in generics. Along with the advantages of these drugs, the ongoing developments and launches are increasing the segment growth.

The growing approval of oral generic drugs, coupled with their increasing adoption due to ease of administration, is anticipated to drive significant growth in this segment during the forecast period. For instance, in August 2024, Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. introduced Ivermectin Tablets USP, 3 mg, which demonstrated bioequivalence and therapeutic equivalence to Merck Sharp and Dohme LLC's STROMECTOL Tablets. This development underscores the rising demand and market potential for oral generic drugs.

The Indian population are used to prefer the medicines administered by the oral route which is likely to boost the market over the forecast period. For instance, according to a study published in the Indian Journal of Pharmaceutical Science in July 2023, oral dosage forms have remained incomparably superior to alternative medication delivery methods. Owing to its formulation convenience, ease of administration, stability, and strong patient compliance, the oral route is the most preferred option. The oral drug delivery method has a great deal of possibilities for combining medications from different classes and dose ranges. Hence, due to the benefits offered the oral route of administration is expected to boost the market over the forecast period.

Hence, increasing launches and advantages associated with oral drug formulation are expected to boost the segment growth over the forecast period.

Respiratory Products Segment is Expected to Witness a Significant Growth Over the Forecast Period

Respiratory diseases encompass ailments that impact the lungs and the broader respiratory system. These diseases can arise from infections, tobacco use, exposure to second-hand smoke, or inhalation of pollutants like radon, asbestos, and other airborne toxins. The respiratory products segment is experiencing robust growth, driven by the increasing prevalence of respiratory disorders and proactive measures from market players, including a surge in product approvals and strategic market expansions. This trend underscores the growing importance of addressing respiratory health challenges and highlights the market's potential for innovation and expansion.

As the burden of respiratory diseases escalates, so does the demand for generic respiratory products, fueling market expansion. For example, a World Health Organization report from October 2024 highlighted that in 2023, India recorded a TB incidence of 195 cases per 100,000 population. With early detection and prompt treatment, there's an anticipated uptick in the adoption of respiratory disease testing, further propelling market growth.

Market players are actively pursuing strategies like product launches and mergers, which are poised to drive market growth in the coming years. For instance, in June 2023, Lupin Ltd secured approval from the United States Food and Drug Administration (USFDA) for its Tiotropium Bromide Inhalation Powder, a generic counterpart to Spiriva HandiHaler. Such strategic initiatives not only enhance the competitive positioning of companies but also expand the availability of cost-effective treatment options, benefiting both the industry and end-users.

In November 2023, Lupin Limited introduced Vilfuro-G in India, marking the introduction of the fixed-dose triple combination drug for the management of chronic obstructive pulmonary disease (COPD). This milestone followed the company's receipt of approval from the Drug Controller General of India, with the product administered through a Dry Powder Inhaler (DPI). This development reflects the industry's commitment to innovation and addressing unmet medical needs, paving the way for improved COPD management and setting a benchmark for future advancements in respiratory care.

Driven by the increasing prevalence of respiratory diseases and the introduction of numerous new products, the segment is expected to experience significant growth in the coming years. The combination of increasing disease burden, strategic initiatives by market players, and advancements in product offerings positions the respiratory products market as a critical area for investment and development, ensuring sustained growth and improved healthcare outcomes globally.

India Generic Drugs Industry Overview

The global generic drugs market is highly competitive, with many players dominating the market. The market players are adopting strategies such as rising R&D investment, mergers, acquisitions, and product innovations to sustain the increasing market rivalry. The key market players include Sun Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Lupin Limited and Aurobindo Pharmaceutical Limited among others.

India Generic Drugs Market Leaders

India Generic Drugs Market News

• January 2025: Bajaj Healthcare obtained approval from the Drug Controller General of India (DCGI) to manufacture a drug targeting the generic treatment of hallucinations and delusions associated with Parkinson's disease. The approval encompasses the production of both the active pharmaceutical ingredient (API) and the drug formulation of Pimavanserin, offered as a 34 mg capsule.
• December 2024: Eli Lilly introduced its flagship drug, Tirzepatide, to the Indian market in 2025. The drug, marketed under the brand name Mounjaro, was intended to address type 2 diabetes and obesity.